J&J, GSK unveil first detailed Phase III sirukumab data

Johnson & Johnson (NYSE:JNJ) and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said sirukumab ( CNTO 136) met the co-primary endpoints in the Phase III SIRROUND-D study to treat moderately to severely active rheumatoid arthritis. The partners plan to submit global regulatory applications in 3Q16 for the human IgG1 kappa mAb against IL-6.

Read the full 515 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE